Every 8-K that Vaxcyte, Inc. (PCVX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PCVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCVX filings page.
Vaxcyte, Inc. (PCVX) completed concurrent equity and debt offerings on October 9, 2026. It issued $575 million aggregate principal amount of 1.50% convertible senior notes due October 15, 2032. Interest is payable semiannually beginning April 15, 2027. The initial conversion rate is 11.1607 shares per $1,000 principal amount, representing an approximately $89.60 per-share conversion price. Before July 15, 2032, holders may convert only upon certain events; from and after that date, they may convert at any time until close of business on the second scheduled trading day before maturity. Vaxcyte may settle conversions in cash, common shares or both, at its election.
The equity offering included 7,412,500 common shares at $64.00 each and pre-funded warrants for 400,000 shares at $63.999 each. Underwriters exercised in full an option for up to 1,171,875 additional common shares on October 7, 2026. Vaxcyte sold the offering securities. Net proceeds were approximately $544.3 million from equity and $558.7 million from debt, after underwriting discounts and commissions and estimated offering expenses payable by Vaxcyte.
Vaxcyte, Inc. (PCVX) reported positive topline results from OPUS-1, its pivotal Phase 3 adult trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. VAX-31 met all prespecified primary immunogenicity endpoints: all 32 immunobridging serotype comparisons met the noninferiority criterion (lower bound of the 95% confidence interval above 0.667), and all four comparisons involving three unique serotypes and cross-reactive 20B met the superiority criterion (lower bound above 2.0).
Among adults 50 and older, VAX-31 met the noninferiority criterion above 0.667 for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21; the two that missed that threshold met the historical threshold above 0.5. Vaxcyte reported that VAX-31 was well tolerated, with a safety profile similar to PCV20 and PCV21 across ages studied. The trial dosed 4,047 participants, including 3,572 aged 50 and older and 475 aged 18–49; immune responses were assessed one month after vaccination. OPUS-2 and OPUS-3 results are anticipated in the first half of 2027, supporting a planned Biologics License Application submission in the first half of 2028, subject to FDA review.
Vaxcyte, Inc. (PCVX) announced senior leadership changes and clarified key clinical timelines. On August 31, 2026, the company appointed David McAvoy as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary, while Mikhail Eydelman continues as Senior Vice President, General Counsel. In a related press release, Vaxcyte also named Luis Jodar, Ph.D., a long-time vaccines leader at Pfizer, as Chief Medical Officer.
The company stated that topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 pivotal trial are now expected by the end of October 2026, narrowing prior guidance that data would be shared in the fourth quarter of 2026. Vaxcyte plans to report Phase 3 data from OPUS-2 and OPUS-3 in the first half of 2027 and is preparing for a planned Biologics License Application submission and potential commercialization of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.
Vaxcyte, Inc. reported a second-quarter 2026 net loss of $284.3 million, compared to $166.6 million a year earlier, as it increased investment in its pneumococcal conjugate vaccine (PCV) programs. Research and development expenses were $267.9 million and general and administrative expenses were $34.9 million. Cash, cash equivalents and investments were $2,507.7 million as of June 30, 2026.
The company reported full enrollment of its three adult VAX-31 Phase 3 OPUS trials and a Phase 2 infant study, with topline OPUS-1 noninferiority data expected in the fourth quarter of 2026 and OPUS-2 and OPUS-3 results in the first half of 2027. A Phase 1 study of VAX-A1 for Group A Streptococcus is underway, with topline data anticipated in the second half of 2027. Management highlighted approximately $2.5 billion in cash and investments as supporting planned clinical, manufacturing and commercial-readiness milestones.
Vaxcyte, Inc. announced that director Heath Lukatch will retire from its Board of Directors effective July 16, 2026, after more than eight years of service. His retirement is stated to not result from any disagreement or dispute with the company.
On the same date, the Board appointed John Markels as a Class II director, with a term expiring at the 2028 annual meeting of stockholders, and named him to the Audit Committee and Compensation Committee. The Board determined he qualifies as an independent director under Nasdaq Rule 5605(a)(2). He will be compensated under the company’s non-employee director compensation program, under which the equivalent value of the annual equity grant for all directors is currently $430,000, and has entered into the company’s standard indemnification agreement.
Vaxcyte, Inc. announced a planned change on its board of directors. On June 17, 2026, long‑serving director Jacks Lee retired from the board, with the company stating his retirement was not due to any disagreement or dispute. He will continue to support Vaxcyte under a consulting agreement focused on global strategic supply and manufacturing operations.
That same day, the board appointed Moncef Slaoui as a Class II independent director, effective immediately, with a term running until the 2028 annual stockholder meeting. He qualifies as an independent director under Nasdaq Rule 5605(a)(2), and the company reports no related‑party transactions requiring disclosure. Slaoui will be compensated under Vaxcyte’s non‑employee director compensation program, which currently sets the equivalent value of the annual equity grant for each director at $430,000, and he has entered into the company’s standard indemnification agreement.
Vaxcyte, Inc. held its Annual Meeting of Stockholders on June 15, 2026, where three Class III directors were re-elected to serve until the 2029 Annual Meeting. Olivier Brandicourt, M.D., Halley Gilbert, J.D., and Grant Pickering, M.B.A. each received strong shareholder support, with Brandicourt and Gilbert receiving over 114 million votes for and Pickering receiving over 132 million votes for, alongside broker non-votes.
Stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with more than 137 million votes in favor. In addition, shareholders approved, on a non-binding, advisory basis, the compensation of the company’s named executive officers, with approximately 130 million votes for, 2.8 million against, and additional abstentions and broker non-votes.
Vaxcyte, Inc. reported first-quarter 2026 results and a broad clinical and manufacturing update. The company is fully enrolled in its three adult Phase 3 OPUS trials of VAX-31 and expects topline OPUS-1 data in the fourth quarter of 2026, with OPUS-2 and OPUS-3 results in the first half of 2027. An infant Phase 2 dose-finding study of VAX-31 has completed enrollment, with topline data from the primary series and booster expected by the end of the first half of 2027. Vaxcyte plans to start a Phase 1 adult trial of its Group A Strep vaccine candidate VAX-A1 in mid-2026. The company completed a February 2026 equity offering of 12,650,000 shares at $50.00 per share, contributing to $2.74 billion in cash, cash equivalents and investments as of March 31, 2026. First-quarter R&D expenses rose to $312.8 million, and net loss widened to $320.6 million, or $2.30 per share.
Vaxcyte, Inc. entered a new at-the-market stock offering program allowing it to sell up to $500,000,000 of common stock through Leerink Partners as placement agent under an existing shelf registration on Form S-3.
The shares may be sold from time to time on Nasdaq or other permitted markets, with Leerink Partners earning up to 3.00% of gross proceeds. Vaxcyte simultaneously terminated its prior Open Market Sale Agreement with Jefferies, under which it had previously sold approximately $270.3 million of common stock.
Vaxcyte, Inc. reported a larger net loss for 2025 while advancing its late-stage pneumococcal vaccine programs and strengthening its balance sheet. The company posted a 2025 net loss of $766.6 million, driven mainly by higher research and development spending of $794.3 million as it moved the VAX-31 adult and infant programs into Phase 3 and Phase 2, respectively, and expanded manufacturing readiness.
Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, not including approximately $600.2 million in net proceeds from a $632.5 million equity offering in February 2026. Vaxcyte highlighted three ongoing Phase 3 adult studies for VAX-31, completed enrollment of a 900-infant Phase 2 study, and plans to start a Phase 1 adult trial for its Group A Strep candidate VAX-A1 in 2026.
Vaxcyte, Inc. entered into an underwriting agreement to issue and sell 11,000,000 shares of common stock at $50.00 per share to the public, with underwriters purchasing at $47.50 per share. The company granted underwriters a 30-day option to buy up to 1,650,000 additional shares, which they exercised in full. Including this option, Vaxcyte expects net proceeds of approximately $600.2 million after underwriting discounts, commissions and estimated expenses. The offering, made under an effective Form S-3 shelf registration, closed on February 2, 2026 and was led by a syndicate of major investment banks.
Vaxcyte, Inc. (PCVX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company states the information in Items 2.02 and 9.01, including Exhibit 99.1, is furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act. Vaxcyte’s common stock trades on The Nasdaq Stock Market LLC under the symbol PCVX.
Vaxcyte, Inc. entered into a long-term Master Services Agreement with Patheon Manufacturing Services, part of Thermo Fisher Scientific, effective September 24, 2025. Patheon will formulate, fill, package, test, manufacture and supply Vaxcyte’s drug product from its Greenville, North Carolina facility.
The agreement includes binding minimum purchase commitments over defined forecast periods at established prices that may be adjusted, along with payments for technology transfer and reimbursement of certain capital expenditures. It has an initial 15-year term and automatically renews for additional three-year periods unless either party gives notice.
Vaxcyte can terminate for convenience or for specified causes, and either party may terminate for insolvency events, uncured legal or regulatory violations, or uncured material breach. If Vaxcyte terminates for convenience, it must pay Patheon at least a fixed amount in the mid-eight-figures or an amount tied to the current forecast plus certain capital commitments, with a different formula applying in the case of a defined Program Failure.